Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2018-04-11, Stock:ABBV, The news for the past five days is as follows:
2018-04-04: NEWS1: Top 5 Biotech Stocks for 2018.NEWS2: Johnson & Johnson’s Valuation in March 2018.NEWS3: Better Dividend Stock to Buy: AbbVie Inc. vs. Pfizer Inc..NEWS4: Better Dividend Stock to Buy: AbbVie Inc. vs. Pfizer Inc..NEWS5: Which Big Pharma CEOs Least Deserved Their Big Pay Increases?.NEWS6: Which Big Pharma CEOs Least Deserved Their Big Pay Increases?.NEWS7: Which Big Pharma CEOs Least Deserved Their Big Pay Increases?.NEWS8: [$$] Investors smart at ailing pharma deals.NEWS9: Better Dividend Stock to Buy: AbbVie Inc. vs. Pfizer Inc..
2018-04-05: NEWS1: After Hours Most Active for Apr 5, 2018 :  CZR, MSFT, KEY, JPM, CSCO, CMCSA, MU, MXIM, GE, NUE, ABBV, PFE.NEWS2: After Hours Most Active for Apr 5, 2018 :  CZR, MSFT, KEY, JPM, CSCO, CMCSA, MU, MXIM, GE, NUE, ABBV, PFE.NEWS3: MARKETS: Stocks bust higher, Facebook fake out, Boeing bump, financials turn green.NEWS4: AbbVie Once Again Settles to Protect Humira Franchise From Biosimilars.NEWS5: Tracking the traders' Q1 moves.NEWS6: AbbVie, Samsung Bioepis in deal; Humira biosimilar U.S. release in 2023.NEWS7: AbbVie Deal Allows Biogen To Launch Humira Copy In Europe.NEWS8: AbbVie in deal with Biogen to delay Humira biosimilar U.S. launch to 2023.NEWS9: AbbVie Announces Global Resolution of HUMIRA® (adalimumab) Patent Disputes with Samsung Bioepis.NEWS10: Biogen, Samsung Bioepis Announce Deal With Abbvie For Imraldi Commercialization.NEWS11: Biogen, Samsung Bioepis Announce Deal With Abbvie For Imraldi Commercialization.
2018-04-06: NEWS1: 3 High-Yield Stocks at Rock-Bottom Prices.NEWS2: A Look at Enanta Pharmaceuticals’ Financial Performance.NEWS3: Analysts’ Ratings for Enanta Pharmaceuticals and Peers in April.NEWS4: Biogen Cracks the Case With AbbVie for Humira Biosimilar.NEWS5: Biogen Cracks the Case With AbbVie for Humira Biosimilar.NEWS6: iShares S&P 500 Growth ETF Experiences Big Outflow.NEWS7: iShares S&P 500 Growth ETF Experiences Big Outflow.NEWS8: Biogen Cracks the Case With AbbVie for Humira Biosimilar.NEWS9: AbbVie to Host First-Quarter 2018 Earnings Conference Call.NEWS10: Cancer killer: Tampa’s ‘best-kept secret’ M2Gen collects data from labs and bedsides to help target treatments.NEWS11: [$$] Samsung, Biogen Reach Deal With AbbVie to Sell Near Copy of Humira.
2018-04-09: NEWS1: AbbVie shares jump 2.2% on news of positive results in rheumatoid arthritis drug trial.NEWS2: AbbVie shares jump 2.2% on news of positive results in rheumatoid arthritis drug trial.NEWS3: Upadacitinib Meets All Primary and Ranked Secondary Endpoints Including Superiority Versus Adalimumab in Phase 3 Study in Rheumatoid Arthritis.NEWS4: 3 Reasons This Clinical-Stage Biotech Is an Incredible Bargain.NEWS5: [$$] Merck eyes best day since 2016, gains help fuel pharma rally.
2018-04-10: NEWS1: AbbVie's RA Candidate Meets Primary Endpoints in Phase III.NEWS2: AbbVie's RA Candidate Meets Primary Endpoints in Phase III.NEWS3: AbbVie&apos;s RA Candidate Meets Primary Endpoints in Phase III.NEWS4: AbbVie Stock Performance in 1Q18.NEWS5: Ex-Dividend Reminder: American Eagle Outfitters, Buckle and AbbVie.NEWS6: Ex-Dividend Reminder: American Eagle Outfitters, Buckle and AbbVie.NEWS7: FDA needs more time to review AbbVie, Neurocrine's uterine pain drug.NEWS8: UPDATE 1-FDA needs more time to review AbbVie, Neurocrine's uterine pain drug.NEWS9: FDA extends review for AbbVie, Neurocrine's uterine pain drug.NEWS10: AbbVie and Neurocrine Biosciences Announce PDUFA Target Date of Q3 2018 for Elagolix in Endometriosis-Associated Pain.NEWS11: See what the IHS Markit Score report has to say about AbbVie Inc..NEWS12: AbbVie : PDUFA Target Date Of Q3 For Elagolix In Endometriosis-Associated Pain.NEWS13: AbbVie : PDUFA Target Date Of Q3 For Elagolix In Endometriosis-Associated Pain.NEWS14: ABBV's SELECT-COMPARE Hits Goals, MNLO's ATOMIK Flops, VTVT Down 63% After-Hrs.NEWS15: ABBV's SELECT-COMPARE Hits Goals, MNLO's ATOMIK Flops, VTVT Down 63% After-Hrs.

Answer: Rise